Oxaluria evolution.

PreclinicalSmall molecule

Oxaluria evolution. is one of 2 small molecule programs targeting Primary Hyperoxaluria Type 1. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Hyperoxaluria Type 1Active, not recruiting

Primary Hyperoxaluria Type 1Preclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Primary Hyperoxaluria Type 1

#DrugCompanyPhaseTrials

Rivfloza

Novo Nordisk

Preclinical

1 2

Oxaluria evolution.

HHospices Civils de Lyon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Primary Hyperoxaluria Type 1

NCT06225882

Clinical

Trials by Indication[1]

Primary Hyperoxaluria Type 11 trial

Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.

Recruiting·HHospices Civils de Lyon··NCT06225882·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oxaluria evolution.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxaluria evolution. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxaluria evolution.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHospices Civils de Lyon

Oxaluria evolution.

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Primary Hyperoxaluria Type 11 trial

References

Drug Info

Quick Facts

Related News